Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 2Breast Neoplasms, Male 2Stomach Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Glioblastoma 1Esophageal Neoplasms 1

Interventions

pembrolizumab 3fludarabine 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1temsirolimus 1spartalizumab 1sonidegib 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1ridaforolimus 1pazopanib 1motexafin gadolinium 1lenvatinib 1durvalumab 1depatuxizumab mafodotin 1cediranib 1cc-486 1carboxyamido-triazole 1abiraterone 1Thalidomide 1Temozolomide 1Sorafenib 1Sirolimus 1Radiation 1Quality of Life 1Proton Pump Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × MK 2206 × Breast × Clear all
NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Merck Sharp & Dohme LLC

Phase 1 Completed
65 enrolled
BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡